Key Points
- Alphatec COO Scott Lish sold 260,535 shares on March 13 at an average price of $12.30 for about $3.20 million, cutting his holding by 24.21% to 815,704 shares (≈$10.03M).
- Alphatec beat expectations in its latest quarter with $0.06 EPS vs. $0.04 expected and revenue of $212.93 million, up 20.4% year-over-year.
- Analyst sentiment is generally positive—ten Buys, one Hold and one Sell—with a consensus rating of “Moderate Buy” and a price target of $22.82.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 260,535 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $12.30, for a total value of $3,204,580.50. Following the sale, the chief operating officer directly owned 815,704 shares of the company's stock, valued at approximately $10,033,159.20. This represents a 24.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Alphatec Stock Performance
Shares of NASDAQ ATEC opened at $13.05 on Wednesday. The stock's fifty day simple moving average is $14.76 and its 200 day simple moving average is $16.84. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -13.74 and a beta of 1.02. The company has a quick ratio of 1.28, a current ratio of 2.06 and a debt-to-equity ratio of 40.35. Alphatec Holdings, Inc. has a 52-week low of $8.81 and a 52-week high of $23.29.
Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $212.93 million for the quarter, compared to analysts' expectations of $212.67 million. During the same period in the prior year, the company earned ($0.23) earnings per share. The company's revenue for the quarter was up 20.4% on a year-over-year basis. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alphatec
A number of institutional investors have recently bought and sold shares of ATEC. Creative Planning grew its stake in Alphatec by 0.9% during the 3rd quarter. Creative Planning now owns 58,654 shares of the medical technology company's stock valued at $853,000 after acquiring an additional 534 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Alphatec by 2.1% in the third quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company's stock worth $600,000 after purchasing an additional 846 shares in the last quarter. Norden Group LLC lifted its position in shares of Alphatec by 2.6% in the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company's stock worth $533,000 after purchasing an additional 939 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Alphatec by 2.8% during the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company's stock worth $503,000 after purchasing an additional 949 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Alphatec by 8.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company's stock worth $131,000 after purchasing an additional 955 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. TD Cowen reaffirmed a "buy" rating on shares of Alphatec in a research note on Tuesday, January 27th. Barclays lifted their target price on shares of Alphatec from $23.00 to $27.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 7th. Stifel Nicolaus reduced their price target on shares of Alphatec from $24.00 to $20.00 and set a "buy" rating for the company in a research report on Monday, March 9th. Morgan Stanley set a $23.00 price objective on shares of Alphatec in a research note on Tuesday, December 2nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Alphatec in a research report on Monday, January 12th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alphatec currently has an average rating of "Moderate Buy" and a consensus price target of $22.82.
View Our Latest Stock Report on Alphatec
About Alphatec
(
Get Free Report)
Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.
Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
